

Efficacy and Safety of Different Prophylactic Doses of Phenylephrine for Prevention of Spinal Anaesthesia induced Hypotension in Cesarean Section-A Randomised Controlled Trial

CHANCHAL KUMAR DALAI¹, SOUMITA ROY², MADHUMITA RAY³, ABHISHEK GHOSH⁴

ABSTRACT

Introduction: Spinal anaesthesia is a standard technique for elective caesarean section. But, hypotension is the main complication, which adversely affects both mother and foetus.

Aim: To evaluate the efficacy and safety of different prophylactic doses of phenylephrine for prevention of spinal anaesthesia induced hypotension.

Materials and Methods: This prospective, randomised, double blinded controlled study was conducted on 104 pregnant mothers who fulfilled the subject selection criteria. Patients were randomly allocated into four groups: Group A received 2 mL of 0.9% saline solution Intramuscularly (IM), Group B, Group C and Group D received 1 mg, 2 mg, and 3 mg of phenylephrine (made in 2 mL of 0.9% saline) IM, respectively. Hyperbaric bupivacaine 0.5%, 2.5 mL was administered intrathecally to all subjects. Haemodynamic parameters: Systolic Blood Pressure (SBP), Mean arterial Blood Pressure (MBP), Diastolic Blood

Pressure (DBP), Heart Rate (HR) were recorded throughout the surgery at three minutes interval and 10 minutes interval for one hour after surgery (study period). Adverse events were also noted throughout the study period.

Fisher's exact test, Kruskall-Wallis test, Friedman's ANOVA were done for statistical analysis.

Results: Subjects of Group D had least episode of hypotension (2 times) than Group A (13 times). Subjects of Group D required least amount of rescue medication (73.91 \pm 22.85 mcg) than Group A (435 \pm 39.25 mcg) that was statistically significant (p<0.001). Incidence of nausea and vomiting were least in subjects of Group D (7.69%) than Group A (66.67%) which was statistically significant (p<0.001).

Conclusion: Prophylactic 3 mg IM phenylephrine is effective to lower the incidence of spinal anaesthesia induced hypotension in elective caesarean section with minimal tolerable adverse effects.

Keywords: Anaesthetic techniques, Double blinded study, Phenylephrine

INTRODUCTION

Spinal anaesthesia is a standard technique for elective caesarean section [1]. However, hypotension is the main complication with this technique. The incidence of hypotension is more than 80% without any prophylactic measure [2].

As a consequence, of spinal anaesthesia sympathetic block occurs, venous return to the heart is decreased, ultimately causes hypotension and decreased cardiac output. This hypotension with or without bradycardia has adverse effects on both mother (nausea, vomiting, dysnoea, cardiovascular collapse etc.) and foetus (acidosis, neurologic injuries etc.) [2-4].

The incidence of hypotension can be lowered by several ways, but no single method is effective for complete prevention of spinal anaesthesia induced hypotension [2].

It is a common practice to give Intravenous Fluids (IVF) before and during spinal anaesthesia to prevent post spinal hypotension. However, fluid preloading is not so much effective, because volume loading does not prevent the spinal anaesthesia induced decreased systemic vascular resistance [5,6].

Now, its a trend to use vasopressors due to its direct vasoconstrictor effects. Vasopressors, like ephedrine or phenylephrine are generally used intravenously, but there is always a chance of raised Heart Rate (HR) and Blood Pressure (BP) [4].

Among all vasopressors, phenylephrine is now the agent of choice in obstetrics [7].

Phenylephrine, a pure α -1 adrenergic agonist, can counteract the decreased systemic vascular resistance induced by spinal anaesthesia without increasing the HR. It is effective when given IM or IV [4]. Phenylephrine is a rapidly acting agent with a short duration of action. Other advantages of phenylephrine include high efficacy, ability to maintain maternal BP near normal.

The usual approach for using phenylephrine in this clinical setting is reactive rather than proactive; spinal anaesthesia induced maternal hypotension is allowed to develop and then treated through intravenous (IV) phenylephrine; however, treatment after onset of hypotension is associated with higher incidence and severity of maternal predelivery hypotension [8].

A more logical approach is to prevent spinal anaesthesia induced hypotension by administrating prophylactic phenylephrine, because this approach inhibits the exposure of mother and foetus to the hypotensive state [8].

Prophylactic administration of IV phenylephrine is associated with a higher incidence of hypertension with or without bradycardia, that's why IV route is not a good choice for prophylactic therapy [7].

IM phenylephrine can be prescribed as prophylactic agent; onset of action of IM phenylephrine is slower than IV phenylephrine, so its onset of action may be matched with time of onset of spinal anaesthesia induced hypotension [6]. Although, literature evidence, is currently inadequate about which dose of IM phenylephrine is sufficient enough to control the spinal anaesthesia induced hypotension in caesarean section with minimal side effects.

On this background, the present study was conducted to determine the efficacy and safety of prophylactic doses of IM phenylephrine for prevention of spinal anaesthesia induced hypotension in caesarean section.

MATERIALS AND METHODS

A double blinded, randomised, interventional, placebo controlled study was conducted from July 2013 to September 2013 in Obstetrics and Gynaecology operation theatre of a tertiary teaching hospital. Institutional Ethics Committee approval letter no. F78/Pr/COMJNMH/I.E.C/42/(27) dated 26/04/2013. CTRI registration no. CTRI/2014/11/005218 dated 21/11/2014.

A power analysis was performed by assuming 70% incidence of hypotension in the control group and revealed that a sample size of 26 patients in each group shall have 90% power to detect a 35% reduction in the incidence of hypotension, with Type I error probability (α) of 0.05 and 10% of dropout [9]. Total sample size was 104 subjects.

After obtaining Institutional Ethics Committee's approval, total 104 pregnant women between 18-30 years, American Society of Anaesthesiologists (ASA) physical status I or II, weight 50-90 kg, height 145-165 cm, having uncomplicated singleton pregnancy beyond 36 weeks, scheduled to have elective caesarean section under spinal anaesthesia were recruited for this study.

Subjects with foetal malpresentation, Pregnancy Induced Hypertension (PIH), hypertensive or resting BP≥160/90 mmHg before surgery, cardiac disease, systemic illness (renal disease, diabetes mellitus, coagulation disorder etc), chronic medications were excluded from the study.

After obtaining written informed consent, subjects were randomly (computer generated random numbers) allocated, where every subject had a chance to get allocated in any group, to receive 0.9% normal saline solution (Group A), or 1 mg of IM phenylephrine (Group B) or 2 mg of IM phenylephrine (Group C), or 3 mg of IM phenylephrine (Group D).

All medication with phenylephrine was made up to 2 mL with 0.9% saline. All patients were managed by an anaesthesiologist who was blind to the identity of the study medication.

No premedication was given to the study patients. Before spinal anaesthesia, 18 gauge IV catheter was introduced in the vein of left forearm of each patient. After that 500 mL IVF Ringer lactate was infused over 15 minutes as preloading. Then Ringer lactate infusion was continued throughout the operation and one hour after the operation at a rate of 4 mL/kg/hr through infusion pump.

Non Invasive Blood Pressure (NIBP), Electrocardiography (ECG) and pulse oximetry were attached for monitoring the BP, HR and O_2 saturation. Baseline SBP, DBP, MBP, HR were recorded. Then, patients were placed in sitting position and after antiseptic dressing and draping, a 25 gauge spinal needle was inserted in L2-3 or L3-4 vertebral inter-space, spinal anaesthetic agent, hyperbaric bupivacaine 0.5%, 2.5 mL was administered intrathecally.

Thereafter, patients were placed supine with left lateral uterine displacement at 15° angle. The IM injection of the study medication was given into the lateral aspect of the right thigh. Then, SBP, DBP, MBP, HR were recorded at three minutes interval throughout the surgery (average time for surgery was 27-30 minutes) (in the present study the average time was 27 minutes) and 10 minutes interval for one hour after surgery [4].

Hypotension was defined as SBP of <90 mmHg or fall of MBP more than 25% from the baseline MBP. Patients who met either criterion were treated with rescue IV bolus dose of phenylephrine 100 mcg. The same dose was repeated in three minute interval if both SBP and MBP would not increase above the threshold levels. Treatment with IV atropine 0.6 mg was given if bradycardia (defined as HR<50 bpm) occured, and if required repetition of the same dose in six minute interval. Subsequently no increase above the threshold level after two rescue dose (either phenylephrine or atropine, or both), the patient was excluded from the study. After delivery of the shoulders of the baby, patients received 5 IU of oxytocin by slow IV.

Efficacy parameters were assessed through the data of SBP, MBP, DBP. Any changes in ECG, HR or any other adverse events were also noted in detail.


STATISTICAL ANALYSIS

Statistical analysis was done only after the completion of Case Record Form (CRF) of the last subject.

Data were represented as mean±SEM. Categorical data were compared between groups by Fisher's exact test. As the data could not pass the normality test, numerical data between the groups were analysed by Kruskall-Wallis (nonparametric) test, whereas within the group were analysed by Friedman's ANOVA (nonparametric) followed by Dunn's Multiple Comparison test as post hoc test. All analyses were two tailed and p<0.05 was taken to be statistically significant.

RESULTS

A total of 104 subjects were randomised during the period of July 2013 to September 2013. Out of 104, 102 completed the study as per protocol, two subjects were excluded from the study as to hypotension was not controlled by rescue medications in (Group A) and needed different medications. There were 24 subjects in Group A (placebo treated group), whereas 26 subjects each in Group B (phenylephrine 1 mg IM), Group C (phenylephrine 2 mg IM) and Group D (phenylephrine 3 mg IM) [Table/Fig-1].



The subjects in all groups had comparable demographic profiles, laboratory parameters and baseline efficacy parameters [Table/ Fig-2].

There were significant changes of SBP in Group A over different time points (compared to the baseline), whereas in Group D, the SBP was maintained (least variability) throughout the surgery except

Parameters	Group A (N=24)	Group B (N=26)	Group C (N=26)	Group D (N=26)	p- value		
Demographic	parameters						
Age (years)	25.15±0.80	25.54±0.76	23.7±0.57	23.43±0.69	0.08		
Gestational age (weeks)	39.09±0.4	38±0.21	37.9±0.16	38.57±0.25	0.33		
Height (cm)	157.7±0.69	155.3±1.58	157.05±0.6	157.26±0.45	0.86		
Weight (kg)	56.77±1.16	57.72±0.84	56.52±0.96	58.47±0.67	0.45		
Laboratory pa	rameters						
Haemoglobin (gm%)	11.3±0.19	11.3±0.21	10.85±0.18	11.4±0.23	0.24		
FBS (mg/dL)	82.55±1.88	83±1.66	82.7±1.78	86.65±1.4	0.14		
PPBS (mg/ dL)	126.6±1.36	128.63±1.17	125.15±1.04	129.13±1.23	0.08		
Urea (mg/dL)	19.77±0.73	19.23±0.71	20±0.74	21.04±0.8	0.4		
Creatinine (mg/dL)	0.59±0.06	0.62±0.02	0.63±0.08	0.66±0.03	0.58		
Efficacy paran	neters						
SBP (mmHg)	128.2±1.77	127.13±1.58	125.7±2.08	121.82±2.61	0.31		
DBP (mmHg)	82.25±1.46	83.9±0.83	80.95±2.1	79.56±2.17	0.69		
MBP (mmHg)	97.5±1.38	98.36±0.9	96±1.99	93.86±2.18	0.58		
PR (beats/ min)	99.45±3.89	99.4±2.95	92.5±2.71	97.95±2.58	0.5		
O ₂ Saturation (SpO ₂ %)	99.2±0.17	99.04±0.26	92.5±2.71	97.95±2.58	0.88		
[Table/Fig-2]: Shows demographic parameters, laboratory parameters, efficacy parameters. FBS-Fasting blood sugar, PPBS-Postprandial blood sugar p-value for comparison of the study groups was from Kruskal Wallis H test (non parametric test).							

p-value for comparison of the study groups was from Kruskal Wallis H test (All parameters were comparable between groups

in SBP-8, (p<0.05), and also throughout one hour of postoperative period. Group C had less fluctuation than Group B in respect of SBP [Table/Fig-3].

The same results were seen in case of DBP [Table/Fig-4], and MBP [Table/Fig-5]. Group D had the least variability [decrease DBP was

seen in DBP-8 (p<0.001), and DBP-9 (p<0.01)] followed by Group C, then Group B.

HR in all groups was steadily maintained in intraoperative as well as first one hour of postoperative period (p>0.05) [Table/Fig-6]. In HR, all groups were comparable, and there was no significant difference in comparison to baseline in all four groups.

Incidence of hypotension [Table/Fig-7] was frequently seen in Group A over different time points, least incidence was observed in Group D.

Group D was better than Group A (p<0.001), Group B (p<0.001) and Group C (p<0.007) in respect of total amount of rescue medication requirement. So, Group D required least amount of rescue medication which is statistically significant [Table/Fig-8,9].

Another analysis was done in respect of how many subjects received rescue medications, it was seen that Group D was better than Group A (p<0.001), Group B (p<0.0002) and Group C (p 0.0019), as to least number of subjects in this group received rescue medication. [Table/Fig-10,11].

Nausea and vomiting were the only adverse effects observed in the patients under study. Here, Group D was better than Group A (p<0.001) and Group B (p=0.0006) but comparable with Group C (p 0.41). Subjects of Group D had least incidence of nausea and vomiting [Table/Fig-12,13]. There was no episode of raised BP or bradycardia observed in the present study.

DISCUSSION

This study reports that 3 mg IM phenylephrine (Group D) is more effective to prevent the spinal anaesthesia induced hypotension in elective caesarean section than other different doses of phenylephrine (1 mg in Group B and 2 mg in Group C). We have not designed our study to include 4 mg of IM phenylephrine. Recent studies observed that haemodynamic control can be achieved with increasing dose of IM phenylephrine [5,6,8]. In another recent study it was observed

	Creating	Group A	4	Group E	3	Group	C Group D		D
	Groups	Mean±SEM	p-value	Mean±SEM	p-value	Mean±SEM	p-value	Mean±SEM	p-value
	Baseline	127.68±1.78		127.13±1.58		125.7±2.08		121.82±2.61	
	1 minute after drug administration	117.8±2.82*	<0.05	113.45±4.12	>0.05	121.35±3.6	>0.05	118.73±2.58	>0.05
	SBP-1 (1+3=4 minutes after drug administration)	107.1±3.87*	<0.05	108.68±4.02**	<0.01	118.45±3.17	>0.05	115.43±3.53	>0.05
	SBP-2 (4+3=7 minutes after drug administration)	108.5±3.28*	<0.05	112.81±3.93*	<0.05	115.95±3.46	>0.05	117.08±3.14	>0.05
	SBP-3 (7+3=10 minutes after drug administration)	106.5±2.81*	<0.05	114.31±3.16	<0.05	112.35±3.98	>0.05	117.39±3.69	>0.05
Systolic	SBP-4 (10+3=13 minutes after drug administration)	102.8±3.02***	<0.001	106.95±2.23***	<0.001	113.85±3.55	>0.05	119.08±3.81	>0.05
blood pres- sure before and during	SBP-5 (13+3=16 minutes after drug administration)	99.8±3.38***	<0.001	105.4±1.97***	<0.001	110.6±3.19*	<0.05	116.6±3.82	>0.05
surgery	SBP-6 (16+3=19 minutes after drug administration)	96.75±1.77***	<0.001	100.95±2.46***	<0.001	105.6±2.83***	<0.001	114.65±3.59	>0.05
	SBP-7 (19+3=22 minutes after drug administration)	99.85±3.01***	<0.001	100.85±3.09***	<0.001	107.4±2.88**	<0.01	112.43±3.51	>0.05
	SBP-8 (22+3=25 minutes after drug administration)	98.94±2.21***	<0.001	100.18±3.03***	<0.001	108±2.76***	<0.001	105.8±2.58*	<0.05
	SBP-9 (25+3=28 minutes after drug administration)	97.23±3.55***	<0.001	104.92±3.39***	<0.001	108.5±3.15*	<0.05	107.39±2.89	>0.05
	SBP-10 (10 minutes after surgery)	99±2.64***	<0.001	102.4±2.92***	<0.001	108.15±2.93**	<0.01	113.6±3.01	>0.05
Systolic	SBP-20 (20 minutes after surgery)	100.45±3.28***	<0.001	105.68±2.45***	<0.001	108.95±2.36*	<0.05	115.47±3.13	>0.05
blood pres-	SBP-30 (30 minutes after surgery)	102.25±2.09***	<0.001	106.63±2.57***	<0.001	111.55±2.56	>0.05	118.3±2.44	>0.05
sure (postopera-	SBP-40 (40 minutes after surgery)	103.25±2.92***	<0.001	111.09±1.63*	<0.05	112.35±2.8	>0.05	118.47±2.02	>0.05
tive)	SBP-50 (50 minutes after surgery)	106.25±2.31*	<0.05	113.63±1.65	<0.05	112.75±3.05	>0.05	120.65±1.47	>0.05
	SBP-60 (60 minutes after surgery)	107.3±2.13*	<0.05	115.45±1.78	<0.05	112.35±2.49	>0.05	120±1.38	>0.05

[Table/Fig-3]: Shows systolic blood pressure at various time period in Group A, Group B, Group C, and Group D.

Statistical analysis for comparisons of SBP within the group (with baseline comparison) was performed by nonparametric Friedman's ANOVA followed by post-hoc analysis by Dunn multiple comparison test.

p-value<0.05 considered significant different with baseline.***=p<0.001, **=p<0.01, *=p<0.05 Least fluctuation of SBP was seen in Group D followed by Group C

Chanchal Kumar Dalai et al., Role of Phenylephrine in Spinal Anaesthesia induced Hypotension

	Omuna	Group	A	Group	В	Group	C	Group	D
	Groups	Mean±SEM	p-value	Mean±SEM	p-value	Mean±SEM	p-value	Mean±SEM	p-value
	Baseline	82.25±1.46		83.3±0.8		80.95±2.1		79.56±2.17	
	1 minute after drug administration	76.55±2.39	>0.05	73.14±2.66	>0.05	75.1±3.63	>0.05	75.26±2.25	>0.05
	DBP-1 (1+3=4 minutes after drug administration)	69.75±2.7	>0.05	68.92±2.38**	<0.01	73.75±2.82	>0.05	73.95±2.27	>0.05
	DBP-2 (4+3=7 minutes after drug administration)	68.65±2.07	>0.05	69.73±2.22**	<0.01	71±2.88	>0.05	73.04±2.23	>0.05
Diastolic blood pres-	DBP-3 (7+3=10 minutes after drug administration)	67.3±2.02*	<0.05	69.37±1.72**	<0.05	69.95±3.13	>0.05	71.69±2.63	>0.05
sure before	DBP-4 (10+3=13 minutes after drug administration)	63.2±2.48***	<0.001	65.45±1.98***	<0.001	69±2.51	>0.05	74.3±3.28	>0.05
and during surgery	DBP-5 (13+3=16 minutes after drug administration)	60.45±3.43***	<0.001	66.51±2.12***	<0.001	66.95±2.73**	<0.01	70.21±3.47	>0.05
	DBP-6 (16+3=19 minutes after drug administration)	58±1.73***	<0.001	60.54±2.11***	<0.001	63.95±2.57***	<0.001	69.43±3.16	>0.05
	DBP-7 (19+3=22 minutes after drug administration)	60.7±2.77***	<0.001	58.8±2.46***	<0.001	67.1±2.35*	<0.05	69±3.17	>0.05
	DBP-8 (22+3=25 minutes after drug administration)	61.42±2.47***	<0.001	58.31±2.24***	<0.001	66.21±2.89**	<0.01	64.23±2.15***	<0.001
	DBP-9 (25+3=28 minutes after drug administration)	65.61±2.24	>0.05	65.38±1.28***	<0.001	68.67±2.08	>0.05	64.44±2.74**	<0.01
	DBP-10 (10 minutes after surgery)	58.9±2.52***	<0.001	61±2.66***	<0.001	67.35±2.64*	<0.05	71±2.28	>0.05
Diastolic	DBP-20 (20 minutes after surgery)	64.1±3.83***	<0.001	63.5±2.03***	<0.001	68.2±2.15*	<0.05	73.91±2.92	>0.05
blood	DBP-30 (30 minutes after surgery)	66.25±1.89**	<0.01	64.5±2***	<0.001	69.6±2.25	>0.05	75.21±1.96	>0.05
pressure (postopera-	DBP-40 (40 minutes after surgery)	64.85±2.18**	<0.01	68.59±1.56**	<0.01	72±1.98	>0.05	75.04±1.7	>0.05
tive)	DBP-50 (50 minutes after surgery)	67.35±1.82	>0.05	69.81±1.09**	<0.05	71.45±1.73	>0.05	76.65±1.44	>0.05
	DBP-60 (60 minutes after surgery)	70.9±1.54	>0.05	71.68±1.33	>0.05	72.4±1.73	>0.05	77.13±1.23	>0.05

[Table/Fig-4]: Shows diastolic blood pressure at various time period in Group A, Group B, Group C, and Group D.

p-value<0.05 considered significant different with baseline. ***p<0.001, **p<0.01, *p<0.05

Least fluctuation of SBP is seen in Group D followed by Group C Result shows minimal fluctuations of DBP in various time periods in Group D

	Crewing	Group	A	Group	В	Group	С	Group	D
	Groups	Mean±SEM	p-value	Mean±SEM	p-value	Mean±SEM	p-value	Mean±SEM	p-value
	Baseline	97.5±1.38		98.36±0.9		96±1.99		93.86±2.18	
	1 minute after drug administration	90.3±2.37	>0.05	86.27±3.17	>0.05	90.8±3.45	>0.05	90.13±2.36	>0.05
	MBP-1 (1+3=4 minutes after drug administration)	82.65±3.14	>0.05	82±2.96***	<0.001	88.7±2.81	>0.05	88.43±2.44	>0.05
	MBP-2 (4+3=7 minutes after drug administration)	82.15±2.47*	<0.05	83.86±2.86**	<0.01	85.7±2.96	>0.05	87.17±2.54	>0.05
Mean arterial blood pres-	MBP-3 (7+3=10 minutes after drug administration)	80.35±2.18*	<0.05	84.77±2.14*	<0.05	84.05±3.26	<0.05	87±2.89	>0.05
sure before	MBP-4 (10+3=13 minutes after drug administration)	76.5±2.57***	<0.001	78.72±2.09***	<0.001	84±2.74*	>0.05	89.26±3.3	>0.05
and during surgery	MBP-5 (13+3=16 minutes after drug administration)	73.45±3.34***	<0.001	79.18±1.96***	<0.001	81.6±2.81**	<0.01	85.65±3.47	>0.05
	MBP-6 (16+3=19 minutes after drug administration)	70.65±1.56***	<0.001	74.04±2.11***	<0.001	77.7±2.53***	<0.001	84.6±3.15	>0.05
	MBP-7 (19+3=22 minutes after drug administration)	73.2±2.66***	<0.001	72.8±2.51***	<0.001	80.5±2.44***	<0.001	83.34±3.2	>0.05
	MBP-8 (22+3=25 minutes after drug administration)	73.94±2.28***	<0.001	72.3±2.32***	<0.001	80.2±2.72**	<0.01	77.76±2.18***	<0.001
	MBP-9 (25+3=28 minutes after drug administration)	74.76±3.01***	<0.001	78.53±1.69***	<0.001	82±2.24**	<0.01	78.67±2.66**	<0.01
	MBP-10 (10 minutes after surgery)	71.8±2.4***	<0.001	74.22±2.39***	<0.001	81.1±2.63**	<0.01	85.17±2.46	>0.05
	MBP-20 (20 minutes after surgery)	75.7±3.53***	<0.001	77.4±2.02***	<0.001	81.8±2.05*	<0.05	88.08±2.85	>0.05
Mean arterial blood pres-	MBP-30 (30 minutes after surgery)	78.25±1.73***	<0.001	78.5±1.98***	<0.001	83.7±2.26	>0.05	89.95±2.08	>0.05
sure (post- operative)	MBP-40 (40 minutes after surgery)	77.3±2.37***	<0.001	82.68±1.4**	<0.01	85.35±2.2	>0.05	89.43±1.71	>0.05
	MBP-50 (50 minutes after surgery)	80.15±1.83*	<0.05	84.4±0.91	>0.05	85.3±2.06	>0.05	91.3±1.36	>0.05
	MBP-60 (60 minutes after surgery)	82.75±1.67	<0.05	86.4±1.25	>0.05	85.05±1.9	>0.05	91.45±1.2	>0.05

[Table/Fig-5]: Shows mean arterial blood pressure at various time period in Group A, Group B, Group C, and Group D.

Statistical analysis for comparisons of MBP within the group (with baseline comparison) were performed by nonparametric Friedman's ANOVA followed by post hoc analysis by Dunn multiple comparison test. p-value<0.05 considered significant different with baseline. ***p<0.001, **p<0.05

that infusion regimen required a higher total dose of phenylephrine to maintain maternal arterial blood pressure at baseline during the predelivery period [10].

Subjects who received 3 mg of IM phenylephrine, hypotensive episodes were minimal among them, consecutively they received minimal amount of rescue medication. In a clinical trial 4 mg and 2 mg phenylephrine was administered to patients to evaluate the reduction of hypotension under spinal anaesthesia, it was observed that the incidence of hypotension was 25% in 4 mg group and 46.66% in group 2 mg. In this study it was concluded that preemptive IM phenylephrine 4 mg reduces the severity of spinal anaesthesia induced hypotension [6].

In a recent study it was observed that prophylactic administration was associated with a higher incidence of hypertension and

bradycardia, but in the present study there was no episode of hypertension or bradycardia [7].

Subjects who received 3 mg IM phenylephrine had least incidence of nausea and vomiting than other groups. Recent meta-analytic technique also suggested that the risk of nausea or vomiting was reduced by almost 80% in the women receiving α -agonists [11].

Use of IV phenylephrine for correcting spinal anaesthesia induced hypotension is well established [11]; however, giving IM phenylephrine before spinal anaesthesia is more controversial due to risks of phenylephrine induced hypertension with or without bradycardia if spinal anaesthesia fails. We justified delaying the administration of IM phenylephrine until induction of spinal anaesthesia.

	Creating	Group	Group A Group		p B Grou		p C Group D		D
	Groups	Mean±SEM	p-value	Mean±SEM	p-value	Mean±SEM	p-value	Mean±SEM	p-value
	Baseline	99.45±3.89		99.4±2.95		92.5±2.71		97.95±2.58	
	1 minute after drug administration	98.6±3.44	>0.05	96.36±4.43	>0.05	93.6±3.22	>0.05	91.56±3.7	>0.05
	HR-1 (1+3=4 minutes after drug administration)	101.4±3.22	>0.05	91.63±4.3	>0.05	91.55±3.52	>0.05	93.82±3.64	>0.05
	HR-2 (4+3=7 minutes after drug administration)	98±3.65	>0.05	89.59±3.76	>0.05	94.05±2.77	>0.05	90.08±2.59	>0.05
	HR-3 (7+3=10 minutes after drug administration)	103.25±2.56	>0.05	86.54±3.12	>0.05	89.8±3.57	>0.05	93.26±3.32	>0.05
Heart rate before	HR-4 (10+3=13 minutes after drug administration)	98.3±3.03	>0.05	89.13±2.63	>0.05	90.35±3.25	>0.05	89.47±2.7	>0.05
and during surgery	HR-5 (13+3=16 minutes after drug administration)	102.15±2.33	>0.05	92.36±2.31	>0.05	92.5±2.93	>0.05	94.43±2.59	>0.05
	HR-6 (16+3=19 minutes after drug administration)	100.2±2.7	>0.05	96.5±3.06	>0.05	92.35±3.08	>0.05	98.04±2.41	>0.05
	HR-7 (19+3=22 minutes after drug administration)	100.95±2.42	>0.05	93.57±3.64	>0.05	93.05±2.9	>0.05	94.26±2.56	>0.05
	HR-8 (22+3=25 minutes after drug administration)	99.78±3.48	>0.05	97.75±4.01	>0.05	88.63±2.73	>0.05	97.14±3.3	>0.05
	HR-9 (25+3=28 minutes after drug administration)	100.76±4.08	>0.05	97.84±3.68	>0.05	92.73±2.58	>0.05	95.22±2.77	>0.05
	HR-10 (10 minutes after surgery)	101.9±2.32	>0.05	95.59±2.83	>0.05	92.2±2.86	>0.05	94.17±2.53	>0.05
	HR-20 (20 minutes after surgery)	102.65±2.38	>0.05	90.36±2.97	>0.05	90.7±2.04	>0.05	93.82±2.13	>0.05
Heart rate	HR-30 (30 minutes after surgery)	100.2±2.25	>0.05	88.18±2.22	>0.05	87.6±2.19	>0.05	91.6±1.86	>0.05
(postoperative)	HR-40 (40 minutes after surgery)	92.8±2.55	>0.05	84.86±2	>0.05	85.7±1.53	>0.05	89.04±1.45	>0.05
	HR-50 (50 minutes after surgery)	90.6±2.45	>0.05	84.86±1.16	>0.05	84.65±1.2	>0.05	89.47±1.32	>0.05
	HR-60 (60 minutes after surgery)	88.55±1.94	>0.05	83.9±1.15	>0.05	84.05±1.02	>0.05	88.12±1.14	>0.05

[Table/Fig-6]: Shows heart rate at various time period in Group A, Group B, Group C, and Group D. Statistical analysis for comparison of heart rate within the group (with baseline comparison) were performed by nonparametric Friedman's ANOVA followed by post hoc analysis by Dunn multiple comparison test. p-value<0.05 considered significant different with baseline.

None	Once	Twice	Thrice	4 times	5 times	6 times	7 times
2	0	2	1	5	7	4	3
4	2	2	1	4	9	3	1
6	11	2	4	2	1	0	0
18	0	5	3	0	0	0	0
	2 4 6 18	2 0 4 2 6 11 18 0	2 0 2 4 2 2 6 11 2 18 0 5	2 0 2 1 4 2 2 1 6 11 2 4 18 0 5 3	None Once Twice Three times 2 0 2 1 5 4 2 2 1 4 6 11 2 4 2 18 0 5 3 0	None Once Iwice Innce times times 2 0 2 1 5 7 4 2 2 1 4 9 6 11 2 4 2 1	None Once Iwice Innce times times times 2 0 2 1 5 7 4 4 2 2 1 4 9 3 6 11 2 4 2 1 0 18 0 5 3 0 0 0

[Table/Fig-7]: Incidence of hypotension in different groups

Rescue medication (mcg)	Group A (N=24)	Group B (N=26)	Group C (N=26)	Group D (N=26)			
Mean±SEM	435±39.25	368.18±46.7	200±38.38	73.91±22.85			
[Table/Fig-8]: Shows requirement of total rescue medication in four different groups.							

Groups	p-value				
Group A vs. Group B	0.44				
Group A vs. Group C	0.0003				
Group A vs. Group D	<0.001				
Group B vs. Group C	0.01				
Group B vs. Group D	<0.001				
Group C vs. Group D	0.007				
[Table/Fig-9]: Shows group-wise comparison of rescue medication requirement. p-value from Mann-Whitney nonparametric t-test<0.05 considered significant. It is seen than Group D subjects received least amount of rescue medication that was statistically significant.					

Rescue medication received	Group A (N=24)	Group B (N=26)	Group C (N=26)	Group D (N=26)		
Yes	22 (91.67%)	22 (84.61%)	20 (76.92%)	8 (30.76%)		
No	2 (8.33%)	4 (15.39%)	6 (23.08%)	18 (69.24%)		
[Table/Fig-10]: Shows number of subjects received rescue medication in four groups.						

Journal of Clinical and	Diagnostic Research	2018 May V/	0-12(5) UC01-UC06

Groups	p-value			
Group A vs. Group B	0.66			
Group A vs. Group C	0.23			
Group A vs. Group D	<0.001			
Group B vs. Group C	0.72			
Group B vs. Group D	0.0002			
Group C vs. Group D	0.0019			
[Table/Fig 11]. Oroug wige comparison of number of subjects received recourse				

[Table/Fig-11]: Group-wise comparison of number of subjects received rescue medication.

p-value from Fisher's Exact test, p<0.05 was considered significant. It is seen that Group D subjects received least number of rescue medication.

Nausea, Vomiting	Group A (N=24)	Group B (N=26)	Group C (N=26)	Group D (N=26)
Yes	16 (66.67%)	14 (53.84%)	5 (19.23%)	2 (7.69%)
No	08 (33.33%)	12 (46.16%)	21 (80.77%)	24 (92.31%)

[Table/Fig-12]: Shows incidence of adverse events in various groups.

Groups	p-value
Group A vs. Group B	0.39
Group A vs. Group C	0.001
Group A vs. Group D	<0.001
Group B vs. Group C	0.02
Group B vs. Group D	0.0006
Group C vs. Group D	0.41
[Table/Fig-13]: Shows group-wise comparison of nausea, vomiting. p-value from Fisher's exact test, p<0.05 was considered significant. It was seen that incidence of adverse effects were least in Group D, but comparable with Group C (p=0.41)	

The timing of IM drug administration to achieve optimum efficacy is mostly unpredictable. Pharmacokinetic studies shows that the peak effect of IM phenylephrine is 10-15 minutes after administration [12]. The onset of subarachnoid block is seen within minutes, initially there were the episodes of hypotension; however, 3 mg IM phenylephrine decreased the frequency and incidence of hypotensive episode thereafter.

It was not possible to administer phenylephrine before spinal anaesthesia, because if there was failure of spinal anaesthesia, the patient would be suffering from phenylephrine induced hypertension with or without bradycardia.

LIMITATION

The present study had some limitation like effect of phenylephrine on foetus was not assessed (umbilical arterial cord pH for foetal acidosis, APGAR score), higher dose group (4 mg IM or above) was not included in this study, drug concentration was not measured.

CONCLUSION

To conclude, it can be said that prophylactic 3 mg IM phenylephrine is effective and safe to reduce the incidence of spinal anaesthesia induced hypotension in caesarean section with minimal adverse effect.

Further study will be needed with larger population (without the above limitations) to detect the ideal IM dose of phenylephrine that will be maximally effective for the prevention of spinal anaesthesia induced hypotension, with minimal adverse effect.

REFERENCES

 Jenkins JG, Khan MM. Anaesthesia for caesarean section: a survey in a UK region from 1992 to 2002. Anaesthesia. 2003;58:1114-08.

- [2] Das S, Mukhopadhyay S, Mandal M, Mandal S, Basu SR. A comparative study of infusions of phenylephrine, ephedrine and phenylephrine plus ephedrine on maternal haemodynamics in elective caesarean section. Indian J Anaesth. 2011;55(6):578-83.
- [3] Stewart A, Fernando R, McDonald S, Hignett R, Jones T, Columb M. The dosedependent effects of phenylephrine for elective cesarean delivery under spinal anesthesia. Anesth Analg. 2010;111(5):1230-37.
- [4] Yadav U, Bharat K. A clinical comparative study of prophylactic infusions of phenylephrine and ephedrine on maternal hemodynamics and fetal acidosis in elective caesarean section. JJPSR. 2012;3(12):5056-61.
- [5] Mitra JK. Prevention of hypotension following spinal anaesthesia in caesarean section-then and now. Kathmandu Univ Med J. 2010;8(32):415-19.
- [6] Ramesh R, Dayananda VP, Bhaskara R. Evaluation of pre-emptive intramuscular phenylephrine at different dose for reduction of hypotension under spinal anaesthesia. International Journal of Recent Trends in Science and Technology. 2014;12(1):137-40.
- [7] Nag DS, Samaddar DP, Chatterjee A, Kumar H, Dembla A. Vasopressors in obstetric anesthesia: a current perspective. World J Clin Cases. 2015;3(1):58-64.
- [8] Ayorinde BT, Buczkowski P, Brown J, Shah J, Buggy DJ. Evaluation of pre-emptive intramuscular phenylephrine and ephedrine for reduction of spinal anaesthesiainduced hypotension during caesarean section. Br J Anaesth. 2001;86(3):372-76.
- [9] Hasanin A, Aiyad A, Elsakka A, Kamel A, Fouad R, Osman M, et al. Leg elevation decreases the incidence of post-spinal hypotension in cesarean section: a randomized controlled trial. BMC Anesthesiol. 2017;17:60.
- [10] Doherty A, Ohashi Y, Downey K, Carvalho JCA. Phenylephrine infusion versus bolus regimens during cesarean delivery under spinal anesthesia: a double-blind randomized clinical trial to assess hemodynamic changes. Anesth Analg. 2012;115(6):1343-50.
- [11] Macarthur A, Riley ET. Obstetric anesthesia controversies: vasopressor choice for postspinal hypotension during cesarean delivery. Int Anesthesiol Clin. 2007;45(1):115-32.
- [12] Najeeb R, Asma A, Hussain MZ, Ommid M, Bashir H, Geelani S et al. Comparative evaluation of prophylactic intramuscular phenylephrine and ephedrine on spinal anaesthesia induced hypotension during caesarean section and their effects on Apgar score and neonatal outcomes. J Evolution of Medical and Dental Sciences. 2015;4(74):12852-60.

PARTICULARS OF CONTRIBUTORS:

- 1. Assistant Professor, Department of Pharmacology, College of Medicine and JNM Hospital, Kalyani, West Bengal, India.
- 2. Intern, Department of Anaesthesiology, College of Medicine and JNM Hospital, Kalyani, West Bengal, India.
- 3. Assistant Professor, Department of Anaesthesiology, College of Medicine and JNM Hospital, Kalyani, West Bengal, India.
- 4. Demonstrator, Department of Pharmacology, College of Medicine and JNM Hospital, Kalyani, West Bengal, India.

NAME, ADDRESS, E-MAIL ID OF THE CORRESPONDING AUTHOR:

Dr. Madhumita Ray,

Assistant Professor, Department of Anaesthesiology, College of Medicine and JNM Hospital, WBUHS, Kalyani, Nadia-741235, West Bengal, India.

E-mail: dr.madhumita.ray@gmail.com, chanchal.dalai8@gmail.com

FINANCIAL OR OTHER COMPETING INTERESTS: None.

Date of Submission: May 23, 2017 Date of Peer Review: Sep 19, 2017 Date of Acceptance: Dec 14, 2017 Date of Publishing: May 01, 2018